Accelerated Partial Breast Irradiation Consensus Statement From the American Society for Radiation Oncology (ASTRO)
- Radiation Oncology Flight, Wilford Hall Medical Center, Lackland AFB, TX (United States)
- Department of Radiation Oncology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA (United States)
- Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (United States)
- Department of Radiation Oncology, University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School, New Brunswick, NJ (United States)
- Department of Radiation Oncology, Duke University Medical School, Durham, NC (United States)
- Shaw Regional Cancer Center, Veil, CO (United States)
- Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA (United States)
- Department of Radiation Oncology, University of North Carolina Medical School, Chapel Hill, NC (United States)
- Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI (United States)
- Department of Radiation Oncology, Juravinski Cancer Center, Hamilton, ON (Canada)
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI (United States)
- Harvard Radiation Oncology Residency Program, Boston, MA (United States)
- Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (United States)
Purpose: To present guidance for patients and physicians regarding the use of accelerated partial-breast irradiation (APBI), based on current published evidence complemented by expert opinion. Methods and Materials: A systematic search of the National Library of Medicine's PubMed database yielded 645 candidate original research articles potentially applicable to APBI. Of these, 4 randomized trials and 38 prospective single-arm studies were identified. A Task Force composed of all authors synthesized the published evidence and, through a series of meetings, reached consensus regarding the recommendations contained herein. Results: The Task Force proposed three patient groups: (1) a 'suitable' group, for whom APBI outside of a clinical trial is acceptable, (2) a 'cautionary' group, for whom caution and concern should be applied when considering APBI outside of a clinical trial, and (3) an 'unsuitable' group, for whom APBI outside of a clinical trial is not generally considered warranted. Patients who choose treatment with APBI should be informed that whole-breast irradiation (WBI) is an established treatment with a much longer track record that has documented long-term effectiveness and safety. Conclusion: Accelerated partial-breast irradiation is a new technology that may ultimately demonstrate long-term effectiveness and safety comparable to that of WBI for selected patients with early breast cancer. This consensus statement is intended to provide guidance regarding the use of APBI outside of a clinical trial and to serve as a framework to promote additional clinical investigations into the optimal role of APBI in the treatment of breast cancer.
- OSTI ID:
- 21276887
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 74, Issue 4; Other Information: DOI: 10.1016/j.ijrobp.2009.02.031; PII: S0360-3016(09)00313-7; Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Limitations of the American Society of Therapeutic Radiology and Oncology Consensus Panel Guidelines on the Use of Accelerated Partial Breast Irradiation
Outcomes in Women Treated With MammoSite Brachytherapy or Whole Breast Irradiation Stratified by ASTRO Accelerated Partial Breast Irradiation Consensus Statement Groups